Biohaven licensed its Kv7 epilepsy platform to SK Biopharmaceuticals ahead of a pivotal readout due later this year. The stock opened below its prior close before rallying 17%.
Biohaven and SK Biopharmaceuticals announced Wednesday a global licensing agreement covering Biohaven's Kv7 ion-channel platform, including lead candidate opakalim, currently in Phase 2/3 trials for focal epilepsy. SK Biopharmaceuticals will pay $350 million at closing and $50 million a year later, for $400 million in near-term committed cash, plus up to $150 million in development and regulatory milestones, and will assume up to $245 million of Biohaven's existing payment obligations to Knopp Biosciences, the platform's prior owner. Together those components add up to "up to $795 million." SK Biopharmaceuticals will also pay tiered royalties, in the mid-teens to low-twenties percent range, on U.S. net sales if opakalim is approved. Pivotal topline data from the RISE3 trial are expected in the second half of 2026.
The headline figure decomposes cleanly: $400 million is committed cash, up to $150 million is contingent on milestones that may never be achieved, and up to $245 million is not new money at all, but the assumption of a liability Biohaven already owed. Less than half of the "$795 million" figure is new, unconditional cash.
Shares opened at $14.24, below the prior close of $14.38, fell to an intraday low near $13.02, then rallied unevenly across the session to close near $16.84, up 17.1%, on roughly 3.2 times average volume. That pattern, an initial dip followed by a gradual, multi-hour recovery, is not the shape of a market immediately convinced the deal is good news.
Biohaven held approximately $238 million in cash after a roughly $137 million second-quarter net loss, so the deal's $400 million in near-term cash meaningfully extends runway ahead of the RISE3 readout without diluting shareholders. RBC's Leonid Timashev called the deal "fairly surprising" and cautioned it does not necessarily suggest the asset was valued at a high premium. Leerink's Marc Goodman framed Biohaven as behaving like an asset investor rather than a company committed to fully commercializing its own pipeline.
Biotech benchmarks were roughly flat on the day, ruling out a sector-wide rally as the explanation for Biohaven's move. Competitor Xenon Pharmaceuticals, which has retained full global rights to its own Kv7-mechanism epilepsy program, gained 5.2% on no identified company-specific news, a move that remains unexplained. The RISE3 readout, expected in the back half of this year, will be the first real test of whether Biohaven's decision to monetize the asset early looks prudent or premature.